Biocomputer From Human Neurons Plays Doom, Raises Ethics

Published Date: 28 Mar 2026

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Read Full News

Latest News

Nodal Response After Chemo Helps Tailor Breast Radiotherapy

Ten-year findings suggest some patients may safely receive less treatment, potentially lowering side effects without raising recurrence risk.

Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe bone pain. A new study suggests a simple solution.

From Pathology to Precision: The Story of Leukemia Therapy

From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care evolved from near-certain death to precise, life-extending therapies.

Canadian Group Calls for Earlier Colorectal Cancer Screening

Modelling shows fewer cases and deaths with screening starting at age 45 years.

Q&A: Nipple-Sparing Mastectomy After Breast Radiation

Although many surgeons avoid it, nipple-sparing mastectomy after radiation is a feasible alternative to skin-sparing mastectomy and may help preserve patients’ psychological well-being.

Triplet Therapy Improves Posttransplant Outcomes in Myeloma

A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared with lenalidomide alone in patients with multiple myeloma.

Todays Updates

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Todays Updates

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Latest News

Ten-year findings suggest some patients may safely receive less treatment, potentially lowering side effects without raising recurrence risk.

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe bone pain. A new study suggests a simple solution.

From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care evolved from near-certain death to precise, life-extending therapies.

Modelling shows fewer cases and deaths with screening starting at age 45 years.

Although many surgeons avoid it, nipple-sparing mastectomy after radiation is a feasible alternative to skin-sparing mastectomy and may help preserve patients’ psychological well-being.

A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared with lenalidomide alone in patients with multiple myeloma.

News All Time

Alternative Medicine for Breast Cancer: Study Raises Concern

Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

Current treatment options include surgery and chemotherapy, but chemotherapy’s benefits are often modest and can cause substantial side effects.

SBRT May Beat Brachytherapy in Prostate Cancer

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

Patients with breast cancer living in states with expanded Medicaid eligibility, have seen survival gains, raising more concerns about the impact of recent changes to the program.

Cancer and HIV Vaccines Enter the Therapeutic Era

Therapeutic vaccines are advancing in oncology and HIV, with the aim of retraining immune responses to target tumors and persistent viral reservoirs with precision.

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Home Screening Appeals to Women Facing Healthcare Barriers

Researchers asked more than 2000 women if they preferred at-home vaginal self-sampling over clinic-based testing to screen for cervical cancer.

Which Salvage Therapy Is Best for Recurrent Prostate Cancer?

Ten-year survival data support salvage focal therapy as an option for patients with localized recurrence after prostate cancer radiotherapy.

PSMA PET: Prostate Cancer Staging Revolution Awaits RCT Data

‘Step by step, little by little, we are learning how to act on this new staging information,’ one investigator says.

Recommended News For You

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.

healthy despite having advanced cancer.

How cancer misinformation exploits the way we think

Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.

Higher Binge Drinking Rates Linked to New Cannabis Laws.

Is Exercise an Effective Treatment for Prostate Cancer?

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

Recommended Articles For You

Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life 

The Statistical Paradigm of Leukemia: From Evolving Epidemiology and Molecular Stratification to Precision Therapies and Future Horizons in Leukemia 

How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement? 

Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI can identify women at risk of breast cancer years in advance: Study

2.

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

3.

An inoperable locally advanced NSCLC trial dubbed "Practice Changing".

4.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

5.

Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC

1.

Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making

2.

Beyond the Surface: Understanding the Silent Menace of Abdominal Hematomas

3.

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients

4.

A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease

5.

Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

2.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

5.

CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot